NCT05748210Recruiting
A Symptom Management Application for Children at the Early Stage of Cancer Survivorship and Their Caregivers
Development and Evaluation of a Symptom Management Mobile Health Application With Personalised Support for Children at the Early Stage of Cancer Survivorship and Their Caregivers
Source: ClinicalTrials.gov · Last updated 10 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this randomized controlled trial is to examine the efficacy of the mHealth app in improving symptoms experienced by children in the early stage of cancer survivorship, including physical function, anxiety, depressive symptoms, fatigue, peer relationships, and pain interference, and at improving the quality of life (QoL) of the children's primary caregivers The main question it aims to answer is whether survivors who receive the symptom management mHealth app intervention will report improved symptoms, i.e., improved physical function; lower levels of anxiety, depressive symptoms, and fatigue; better peer relationships; and lower pain interference 3 months after starting the intervention. Additionally, we hypothesized that the primary caregivers (either the mother or father) would report an improved QoL 3 months after starting the intervention. Participants in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. They are required to complete questionnaires at baseline (during medical follow-up), 1, 2, and 3 months (via electronic-based systems in the mobile app) Besides, semi-structured interviews and will be conducted to examine the usability, feasibility, and acceptability of the intervention.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 11 Jan 2023
- Start date
- 2 Jan 2025
- Primary completion date
- 30 Nov 2025
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Childhood cancers
- NCT number
- NCT05748210
What you commit to
- Study type: Interventional
- Planned participants: 150
- From 2 Jan 2025 to the primary completion date, 30 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Chinese paediatric cancer survivors will be excluded if they
- have cognitive impairments or psychiatric illnesses
- have evidence of secondary malignancy or recurrence
- The primary caregivers of the paediatric cancer survivors (either the mother or father) will be excluded if they have cognitive impairments or psychiatric illnesses.
Other
- are currently participating in other symptom management studies, or
Who the study is looking for
- Chinese paediatric cancer survivors will be included if they
- are aged 9 to 16 years,
- are able to read Chinese and communicate in Chinese,
- have completed active cancer treatment (within the previous 2 years), as early symptom management support is crucial to reduce the symptom burden in survivors and their caregivers throughout their survivorship, and
- have a smartphone or tablet and are willing to install the mHealth app.
- The primary caregiver of the paediatric cancer survivors (either the mother or father)
- are able to read Chinese and communicate in Chinese, and
- have a smartphone or tablet and are willing to install the mHealth app with their children surviving cancer.
Age in the registry: 9 years to 16 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Chinese University of Hong Kong Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.